<DOC>
	<DOCNO>NCT01546935</DOCNO>
	<brief_summary>Currently , treatment child less one year age influenza relate low respiratory tract infection either consider standard registered country . This dismal scenario exist even though influenza relate LRTI significant illness cause morbidity mortality , especially child less 6 month age . Avian influenza report rarely child less one . There data Vietnam data Thailand burden influenza child less one . This young age group suffers high mortality . Oseltamivir may beneficial child . This basis trial .</brief_summary>
	<brief_title>Oseltamivir Influenza Lower Respiratory Tract Infection Children Under One</brief_title>
	<detailed_description>There limit data Thailand aetiology LRTI data mortality hospitalise child . Thai child &lt; 1 year account circa one third LRTIs child treat inpatient influenza isolate 6 ( 2.7 % ) 271 child RSV 44 ( 20 % ) . At Queen Sirikit hospital , Bangkok , influenza A B RSV account approximately 11 % ( 9/80 ) , 2.5 % ( 2/80 ) 6 % ( 5/80 ) child &lt; 1 year , respectively . This study include child underlie disease like congenital heart disease chronic lung disease . A small laboratory series 110 child Siriraj hospital LRTIs infection ( Pilaipan Puthavathana , personal communication ) identify RSV A/B ( 17 % ) , metapneumovirus ( 14 % ) , parainfluenza 1 ( 12 % ) adenovirus ( 12 % ) , influenza B ( 6 % ) , influenza A ( 4 % ) , coronaviruses ( 3 % ) , Parainfluenza 3 ( 2 % ) 2 ( 0 % ) . The number drug register treat influenza limited oral Oseltamivir , amantadine rimantadine inhale zanamivir . As result 2009 influenza A/H1N1 , clinical guideline update include child le one year old . However , regulatory study oseltamivir excluded child 1 year base preclinical data rat death young rat ( 7 day old ) none 14 day old rat give large dos Oseltamivir . Higher concentration Oseltamivir find brain young rat think due immaturity blood brain barrier . There , however , clinical experience Oseltamivir one Japan , Thailand , Germany , USA , additional experience 2009 pH1N1 . The dos use 2 mg/kg bid consistent dose recommend UK child weigh less 15 kg ( 30 mg bid 5 day ) . At Queen Sirikit hospital , Oseltamivir give small number child &lt; 1 year severe influenza good effect ( T. Chotpitayasunondh , unpublished observation ) . This experience similar others i.e . good clinical outcome apparently good tolerability . An Oseltamivir pharmacokinetic study child age 1-5 year show dose 2 mg/kg result plasma-concentration time curve ( AUC ) similar AUC accept adult . However , young child , low AUC level ; never less , still insufficient pharmacokinetics data child one year . The clinical significance reduce vitro sensitivity unclear owe paucity human data mutation likely result reduce antiviral efficacy Oseltamivir adamantanes H1N1 . Furthermore , amantadine treatment influenza frequently result rapid development amantadine resistance H1N1 H2N3 virus , result continue virus replication , thus , make drug less ideal treating influenza . Currently , limit adamantane resistant H1N1 widespread adamantane resistant H3N2 . H3N2 influenza B remain sensitive Oseltamivir . The adamantanes activity influenza B . The emergence resistance pose difficulty treatment influenza child less one oseltamivir represent present optimal choice treat child . Therefore , protocol ass effect oral Oseltamivir dos recommend WHO see applicable Thai child .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Signed informed consent parent/legal guardian . Children le 12 month age first see LRTI moderate severe severity virologically proven influenza respiratory specimen . History fever within 14 day prior presentation ( note : fever presentation require ) plus two following : Cough Difficulty breathe / shortness breath Increased respiratory rate age : &gt; 60/min , age &lt; 2 month &gt; 50/min , age 2 &lt; 12 month , Intercostal recession Use accessory muscle Nasal flare/grunting Crepitations without wheeze A consistent abnormal chest X ray e.g . new infiltrate , hyperinflation Virological evidence influenza follow test : A positive commercial rapid test confirm twice influenza respiratory specimens 2 different anatomical sites* * Any one follow constitutes acceptable respiratory specimen : NPA NP swab throat swab endotracheal aspirate bronchoalveolar lavage sample Exclusion criterion child non avian influenza These : Known allergy Oseltamivir Age ≥ 12 month day hospital admission Illness duration &gt; 14 day day hospital admission Creatinine clearance &lt; 10 mls/min/1.73m2 , include requirement dialysis haemofiltration Exclusion criterion child avian influenza These : Known allergy Oseltamivir Age ≥ 12 month day hospital admission Informed consent obtain Patients follow enrolled : underlying illness prescribe Oseltamivir prior presentation avian influenza : creatinine clearance &lt; 10 mls/min/1.73m2 , include requirement dialysis haemofiltration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Oseltamivir</keyword>
	<keyword>Lower tract respiratory infection</keyword>
</DOC>